Clemence Marcault

Dr. Clemence Marcault

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in Blood
Verified
Journal Article
Closed access
PDF file
CMClemence Marcault
Clemence Marcault
LZLin-Pierre Zhao
Lin-Pierre Zhao
NMNabih Maslah
Nabih Maslah
EVEmmanuelle Verger
Emmanuelle Verger
RORafael Daltro de Oliveira
Rafael Daltro de Oliveira
LBLina Benajiba
Lina Benajiba
Marcault et al report the impact of NFE2 mutations on the prognosis of patients with myeloproliferative neoplasms (MPNs) in a study of over 700 patients for whom sequential next-generation sequencing was available. NFE2 mutations were reported in 9.1% of patients and predicted for increased transformation and decreased survival. Since histone deacetylase (HDAC) inhibitors decrease NFE2 levels, patients with NFE2 mutations may benefit from HDAC inhibitors.

1 March 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
CMClemence Marcault
Clemence Marcault
NBNicolas Boissel
Nicolas Boissel
CHClaudia Haferlach
Claudia Haferlach
MLMichael Loschi
Michael Loschi
SRSophie Raynaud
Sophie Raynaud
TCThomas Cluzeau
Thomas Cluzeau

8 June 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CMClemence Marcault
Clemence Marcault
SFSofiane Fodil
Sofiane Fodil
TDThibault Dupont
Thibault Dupont
MDMichael Darmon
Michael Darmon
EAElie Azoulay
Elie Azoulay
Click on the article title to read more.